Tissue Engineering Market: Growth, Size, Share, and Trends

Market Growth Outlook Summary

The global tissue engineering market growth forecasted to transform from USD 4.4 billion in 2023 to USD 8.9 billion by 2028, driven by a CAGR of 15.3%. The growth of this market is largely driven by the emergence of promising technologies, including 3D bioprinting, and rising demand for advanced solutions for damaged tissue repair and regeneration.

Tissue Engineering Market Trends

To know about the assumptions considered for the study, Request for Free Sample Report

Attractive Opportunities in the Tissue Engineering Market

Global Tissue Engineering Market Dynamics

Driver: Growing need for regenerative medicines

The increasing demand for advanced regenerative medicines for the treatment of chronic and degenerative diseases is accelerating the growth of the tissue engineering market. The rising rate of degenerative diseases and increasing incidences of road accidents are promoting the demand for regenerative medicines, resulting in the growth of the tissue engineering market. For instance, according to the Centers for Disease Control and Prevention (CDC) in the United States, each day, around 190 people died from Traumatic Brain Injury (TBI) in 2021. In addition, according to the CDC, every year, around 1.35 million individuals die in road accidents worldwide.

Restraint: High treatment cost

The advanced tissue engineering technologies used for the treatment of chronic and degenerative disorders are expensive. The tissue engineered products are associated with high quality biomaterials, growth factors, living cells, scaffolds, and functional matrices. Therefore, tissue engineering therapy is expensive. Thus, high treatment costs are hampering the growth of the tissue engineering market.

Opportunity: Increasing technological advancements such as 3D printing and Quantum Magnetic Resonance Therapy (QMRT)

The various technological developments in the field of tissue engineering including 3D printing, organ-on-chip technology, and Quantum Magnetic Resonance Therapy (QMRT), are expected to promote the growth of the tissue engineering market. For instance, Cytotron, a therapeutic device associated with Quantum Magnetic Resonance Therapy (QMRT) is used for the treatment of cancer as well as orthopedic diseases. The therapy is used for tissue degeneration in cancer and tissue regrowth in musculoskeletal diseases.

Challenge: Cost effective traditional organ transplant techniques

Organ transplantation technique is the medical process of removal of organs or tissue from the human body and surgically transplanted into recipients. The organ transplantation technique is quite cost-effective as compared to the technologically advanced tissue engineering therapy. Therefore, the cost effectiveness of traditional organ transplant techniques can be one of the major challenging factors for the growth of the tissue engineering market.

Global Tissue Engineering Market Ecosystem Analysis

The ecosystem of tissue engineering consists of end users from hospitals, specialty clinics, ambulatory surgical centers, transplant centers, tissue engineering product and service providers, technology providers, regulatory authorities (ensuring compliance and safety), and collaborative networks promoting knowledge sharing and collaboration. These stakeholders interact and collaborate to drive the advancement of tissue engineering products, enhance drug discovery processes, and develop new therapeutics.

The scaffold segment is expected to register the fastest growth in tissue engineering industry during the forecast period.

Based on the product type of tissue engineering, the market has been segmented into scaffolds, tissue grafts, and other products. In 2022, scaffold segment accounted for the largest share and is expected to grow during the forecast period. The scaffold segment's dominance is due to the booming healthcare industry and increasing technological developments in regenerative medicines.

Orthopedics and musculoskeletal disorders held a dominant share in the application segment in the tissue engineering industry.

Based on the application, the tissue engineering market has been segmented into orthopedics & musculoskeletal disorders, dental disorders, cardiovascular diseases, dermatology & wound care, and others. In 2022, orthopedics & musculoskeletal disorders hold the largest share of the tissue engineering market due to the increasing rate of road accidents and rising incidences of chronic disorders. The increasing rate of road accidents drives the demand for innovative tissue regeneration solutions to repair and reconstruct damaged tissues.

North America accounted for the largest share of the tissue engineering industry in 2022.

To know about the assumptions considered for the study, download the pdf brochure

Geographically, the tissue engineering market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America held the dominant share followed by Europe. The booming healthcare sector and growing research activities in the tissue engineering field are the major factors for the dominance of the North American region in the tissue engineering market. Additionally, the increasing rate of degenerative diseases is promoting the growth of the tissue engineering market in the North American region.

Key players in the global tissue engineering market include Organogenesis (US), AbbVie Inc. (US), Baxter (US), BD (US), B. Braun (Germany), TEIJIN Limited (Japan), Institut Straumann AG (Switzerland), Integra Lifesciences (US), Johnson & Johnson Services, Inc. (US), Medtronic (Ireland), NuVasive, Inc. (US), Stryker (US), Terumo Corporation (Japan), W. L. Gore & Associates Inc. (US), Zimmer Biomet (US), Smith & Nephew plc (UK), MIMEDX Group, Inc. (US), BioTissue (US), CollPlant Biotechnologies Ltd. (Israel), Sumitomo Pharma Co., Ltd. (Japan), Matricel GmbH (Germany), Mallinckrodt (US), Regrow Biosciences Pvt Ltd (India), Vericel Corporation (US), Tecnoss S.R.L. (Italy), Tegoscience (South Korea), and Tissue Regenix (UK).

Scope of the Tissue Engineering Industry

This report categorizes the tissue engineering market to forecast revenue and analyze trends in each of the following submarkets:

By Product Type

• Scaffold, By Material
  • Synthetic Material
  • Biological Material
    • Collagen
    • Hydrogel
    • Stem Cells
    • Others
• Tissue Grafts, By Type
  • Allograft
  • Autograft
  • Synthetic Grafts
  • Xenograft
• Other Products

By Material

• Synthetic Material
• Biologically Derived Material

By Application

• Orthopedics & Musculoskeletal Disorders
• Dermatology & Wound Care
• Dental Disorders
• Cardiovascular Diseases
• Others

By End User

• Hospitals
• Specialty Centers and Clinics
• Ambulatory Surgical Centers

By Region

• North America
  • US
  • Canada
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Rest of Europe (RoE)
• Asia Pacific (APAC)
  • Japan
  • China
  • India
  • South Korea
  • Rest of Asia Pacific (RoAPAC)
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America (RoLATAM)
• Middle East & Africa
• Middle East
• Africa

Recent Developments of Tissue Engineering Industry

• In September 2023, MIMEDX Group Inc. launched EPIEFFECT to broaden its advanced wound care product portfolio. EPIEFFECT is a lyophilized human placental-based allograft consisting of amnion and chorion membranes.
• In July 2023, Teijin Limited launched SYNFOLIUM, a cardiovascular surgical patch and received manufacturing and marketing approval in Japan. The cardiovascular surgical patch is used for the surgical treatment of congenital heart disease (CHD).
• In July 2021, Integra Lifesciences introduced SurgiMend, a collagen matrix. The product is used for soft tissue repair and reconstruction.
• In May 2020, AbbVie Inc. (US) acquired Allergan plc (Ireland) to expand the product portfolio in therapeutics categories. Allergan plc provides new growth opportunities to AbbVie Inc. in neuroscience with Vraylar, Botox therapeutics, and global aesthetics business.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst